Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese

Cancer Genetics and Cytogenetics

Volumn 202, Issue 2, 2010, Pages 76-81

  Xu, Bin ^a,b   Xu, Zheng ^a   Cheng, Gong ^a   Min, Zhi Chao ^a   Mi, Yuanyuan ^a   Zhang, Zhi zhong ^b   Tao, Jun ^a   Li, Peng Chao ^a   Wang, Mei Lin ^b   Tang, Jia Lin ^b   Zhang, Zheng Dong ^b   Zhang, Wei ^a   Wu, Hong Fei ^c   Feng, Ning Han ^a   Hua, Li Xin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE AFFILIATED BENQ HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; CODON; MDM2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CODON; CONTROLLED STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEIN VARIANT; RISK ASSESSMENT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; DEMOGRAPHY; ETHNIC GROUP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; STAINING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CODON; DEMOGRAPHY; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; STAINING AND LABELING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957079533     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.02.014     Document Type: Article

References (18)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Ntais C., Polycarpou A., Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003, 149:469-477.
3. Zhang P., Wei Q., Li X., Wang K., Zeng H., Bu H., et al. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet 2009, 191:73-77.
4. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
5. Ara S., Lee P.S., Hansen M.F., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990, 18:4961.
6. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100.
7. Henner W.D., Evans A.J., Hough K.M., Harris E.L., Lowe B.A., Beer T.M. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001, 49:263-266.
8. Huang S.P., Wu W.J., Chang W.S., Wu M.T., Chen Y.Y., Chen Y.J., et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:2217-2224.
9. Freedman D.A., Wu L., Levine A.J. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999, 55:96-107.
10. Momand J., Zambetti G.P. Mdm-2: " big brother" of p53. J Cell Biochem 1997, 64:343-352.
11. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860.
12. Bond G.L., Hu W., Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005, 65:5481-5484.
13. Wang M., Zhang Z., Zhu H., Fu G., Wang S., Wu D., et al. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res 2008, 14:3633-3640.
14. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50:125-128.
15. Wu W.J., Kakehi Y., Habuchi T., Kinoshita H., Ogawa O., Terachi T., et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 1995, 86:730-736.
16. Stoehr R., Hitzenbichler F., Kneitz B., Hammerschmied C.G., Burger M., Tannapfel A., et al. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br J Cancer 2008, 99:78-82.
17. Li C., Wu W., Liu J., Qian L., Li A., Yang K., et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 2006, 16:245-251.
18. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000, 92:1764-1772.